Dr Derek Connolly
The COMPASS trial was a landmark study demonstrating the benefits of low-dose (vascular dose) rivaroxaban in patients at high risk of cardiovascular events. This module provides an overview of the rational behind the COMPASS trial, the trial design and top-line results of the trial.
Bayer have supported the videos through an unrestricted grant and have no influence on the faculty or content.
This module was filmed in May 2019.